22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
On this episode of Williams Mullen's Benefits Companion, Brydon DeWitt is joined by Larry Parker, pa...
Read More >
California Gov. Gavin Newsom signed Assembly Bill (AB) 5 into law on Sept. 18, 2019, codifying the s...
Read More >
Our "2020 securities, shareholder, and M&A litigation outlook" provides our point of view on 2020, i...
Read More >
Under Delaware law, indirect controllers of a Delaware limited liability company (“LLC”) can owe l...
Read More >
Working to clarify the jumbled mess of FLSA tipped worker regulations, on October 8, 2019, the Depar...
Read More >
As discussed in a previous alert, the 2018–19 New York State budget included provisions designed to...
Read More >